07:00 , May 17, 2010 |  BC Week In Review  |  Clinical News

MDRNA preclinical data

In a mouse model of orthotopic bladder cancer, intravesical delivery of UsiRNAs targeting fibroblast growth factor-3 (FGF-3; INT2 ) and survivin in a single formulation reduced both tumor bioluminescence and survivin mRNA expression by about...